An analysis of cost-saving in the German statutory health insurance system due to the introduction of epoetin alfa biosimilars in Germany.
Saved in:
| Title: | An analysis of cost-saving in the German statutory health insurance system due to the introduction of epoetin alfa biosimilars in Germany. |
|---|---|
| Authors: | Raitner I; Sandoz Deutschland/Hexal AG, Holzkirchen, Germany., Müller B; Sandoz Deutschland/Hexal AG, Holzkirchen, Germany., Vijayan A; Institute for Pharmacology and Preventive Medicine, Cloppenburg, Germany., Zimmermann L; Institute for Pharmacology and Preventive Medicine, Cloppenburg, Germany., Bramlage P; Institute for Pharmacology and Preventive Medicine, Cloppenburg, Germany., Ness NH; Sandoz Deutschland/Hexal AG, Holzkirchen, Germany., Müller M; Sandoz Deutschland/Hexal AG, Holzkirchen, Germany. |
| Source: | Frontiers in public health [Front Public Health] 2025 Dec 16; Vol. 13, pp. 1667315. Date of Electronic Publication: 2025 Dec 16 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Editorial Office Country of Publication: Switzerland NLM ID: 101616579 Publication Model: eCollection Cited Medium: Internet ISSN: 2296-2565 (Electronic) Linking ISSN: 22962565 NLM ISO Abbreviation: Front Public Health Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2296-2565 |
|---|---|
| DOI: | 10.3389/fpubh.2025.1667315 |
